← Research library / Metabolic

5-amino-1MQ: What the Evidence Actually Shows

Preclinical onlyNo approval

The short version

  • Not a peptide. It is a small molecule, sold alongside peptides for marketing reasons.
  • Inhibits NNMT, an enzyme involved in fat cell metabolism and NAD+ salvage.
  • Mouse data only. No human trials of any size.
  • Usually sold as capsules rather than injectable.
  • No approval anywhere.

What it is

Nicotinamide N-methyltransferase, or NNMT, is an enzyme that is upregulated in the fat tissue of obese animals. Inhibiting it in mice reduced fat mass without reducing food intake, which is a genuinely interesting result because it implies an effect on energy expenditure rather than appetite.

5-amino-1MQ is one of the compounds used in that research.

Where the evidence stops

At the mice. That is not a dismissal, it is a description. The published work is preclinical, and there is no human pharmacokinetic data, no human safety data and no human efficacy data.

NNMT also has roles beyond fat tissue, including in NAD+ metabolism and in some cancers, where its expression patterns are complex. Inhibiting an enzyme with multiple roles, without human safety data, is a bigger unknown than the marketing suggests.

What this will not do

Related

Full library · Safety and sourcing · Reconstitution calculator · The 2026 regulatory picture

Regulatory status current as of the page date. This area is changing quickly and this page is reviewed monthly.